Aldeyra Therapeutics (ALDX) said Wednesday it remains on track to submit a new drug application for dry eye disease drug candidate reproxalap in Q4,...
Aldeyra Therapeutics (ALDX) reported Friday a Q2 net loss per share of $0.30, widening from a loss of $0.28 a year earlier. Analysts polled by Capital IQ...
...
Health care stocks were leaning lower premarket Tuesday. The Health Care SPDR (XLV) was down 0.33% and the iShares NASDAQ Biotechnology Index (IBB) was...
| Address | 131 Hartwell Avenue Lexington, Massachusetts 02421 |
| Phone | +1.781.761.4904 |
| Number of Employees | 19 |
| Recent SEC Filing | 09/14/2022 8-K |
| President, Chief Executive Officer & Director | Todd C. Brady |
| Chief Financial Officer, Treasurer & VP-Finance | Bruce Greenberg |
| Senior Vice President-Clinical Development | James A. Gow |
| Chief Development Officer | Stephen G. Machatha |
| Price Open | $5.70 |
| Previous Close | $5.77 |
| 52 Week Range | $2.36 - 9.74 |
| Market Capitalization | $317.3 M |
| Shares Outstanding | 58.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/27/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.14 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -33.47% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
